Roivant Sciences Future Growth
Future criteria checks 2/6
Roivant Sciences's earnings are forecast to decline at 52% per annum while its annual revenue is expected to grow at 37.5% per year. EPS is expected to decline by 54.9% per annum. Return on equity is forecast to be -32% in 3 years.
Key information
-52.0%
Earnings growth rate
-54.9%
EPS growth rate
| Biotechs earnings growth | 23.7% |
| Revenue growth rate | 37.5% |
| Future return on equity | -32.0% |
| Analyst coverage | Good |
| Last updated | 02 May 2024 |
Recent future growth updates
Recent updates
Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success
Mar 18We Believe Roivant Sciences' (NASDAQ:ROIV) Earnings Are A Poor Guide For Its Profitability
Feb 21
These Analysts Just Made A Decent Downgrade To Their Roivant Sciences Ltd. (NASDAQ:ROIV) EPS Forecasts
Nov 15Are Investors Undervaluing Roivant Sciences Ltd. (NASDAQ:ROIV) By 21%?
Apr 26Broker Revenue Forecasts For Roivant Sciences Ltd. (NASDAQ:ROIV) Are Surging Higher
Nov 22Newsflash: Roivant Sciences Ltd. (NASDAQ:ROIV) Analysts Have Been Trimming Their Revenue Forecasts
Sep 29Roivant Sciences Ltd. (NASDAQ:ROIV) Analysts Are Reducing Their Forecasts For This Year
Aug 21Roivant Sciences GAAP EPS of -$0.48, revenue of $4.32M
Aug 15An Intrinsic Calculation For Roivant Sciences Ltd. (NASDAQ:ROIV) Suggests It's 22% Undervalued
Aug 12Roivant Sciences Ltd. (NASDAQ:ROIV) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Jun 30Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2027 | 809 | -655 | -770 | -594 | 6 |
| 3/31/2026 | 323 | -1,021 | -1,052 | -1,023 | 8 |
| 3/31/2025 | 166 | -1,008 | -1,102 | -1,108 | 10 |
| 3/31/2024 | 663 | 4,254 | -962 | 590 | 10 |
| 12/31/2023 | 123 | 4,352 | -839 | -836 | N/A |
| 9/30/2023 | 103 | -1,096 | -851 | -848 | N/A |
| 6/30/2023 | 79 | -1,084 | -987 | -841 | N/A |
| 3/31/2023 | 61 | -1,124 | -996 | -843 | N/A |
| 12/31/2022 | 43 | -1,245 | -969 | -812 | N/A |
| 9/30/2022 | 50 | -1,178 | -1,021 | -858 | N/A |
| 6/30/2022 | 52 | -1,095 | -811 | -789 | N/A |
| 3/31/2022 | 55 | -845 | -695 | -678 | N/A |
| 12/31/2021 | 61 | -1,085 | -652 | -636 | N/A |
| 9/30/2021 | 43 | -1,061 | -614 | -605 | N/A |
| 6/30/2021 | 30 | -888 | -590 | -582 | N/A |
| 3/31/2021 | 24 | -809 | -558 | -552 | N/A |
| 12/31/2020 | 72 | -360 | -535 | -531 | N/A |
| 3/31/2020 | 68 | -456 | -764 | -759 | N/A |
| 3/31/2019 | 2 | -613 | -1,035 | -1,024 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ROIV's earnings are forecast to decline over the next 3 years (-52% per year).
Earnings vs Market: ROIV's earnings are forecast to decline over the next 3 years (-52% per year).
High Growth Earnings: ROIV's earnings are forecast to decline over the next 3 years.
Revenue vs Market: ROIV's revenue (37.5% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: ROIV's revenue (37.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ROIV is forecast to be unprofitable in 3 years.